TY - JOUR T1 - The effect of Rat mesenchymal stem cells and its soluble factors on peripheral blood neutrophil function TT - اثر سلول بنیادی مزانشیمی ‌رت و فاکتورهای محلول ناشی از آن بر عملکرد نوتروفیل خون محیطی JF - yums-armaghan JO - yums-armaghan VL - 19 IS - 1 UR - http://armaghanj.yums.ac.ir/article-1-222-en.html Y1 - 2014 SP - 36 EP - 46 KW - Mesenchymal Stem Cells KW - Soluble Factors KW - Neutrophil Phagocytosis N2 - Background & aim: Mesenchymal stem cells (MSCs) are a population of adult stem cells which is an appropriate source for therapeutic purposes. The aim of this study was to investigate the effects of rat mesenchymal cells and soluble factors on the function of peripheral blood neutrophils. Methods:This experimental study was conducted on rat mesenchymal stem cells. Mesenchymal cells obtained from bone marrow of the femur and Tybaof 6-8 week rats and were cultured in DMEM. After maturation, the mesenchymal cells and supernatant at ratios of 1:4, 1:2 and 3:4 were adjacent with peripheral blood neutrophil phagocytosis. Subsequently, the respiratory burst of neutrophils, the yeast phagocytosis and nitroblue tetrazolium test was evaluated for revival. The Data were analyzed by t-tests, ANOVA and Tukey's test (p ˂0.05). Results:The rates of phagocyted neutrophil treated with MSCs compared to controls were decreased.This reduction was not statistically significant (p >0.05).The phagocitic cell in the rats of the treated group with supernatant compared to the control group in all three ratios of 1:4, 1:2, 3:4 increased significantly (p>0.05). by the increase in the ratio was observed (P>0.05). Respiratory burst of neutrophils treated with mesenchymal stem cells compared to the control group significantly decreased. Respiratory burst was increased in the groups treated with cell supernatant at ratios of 1:2 only (P>0.05). Conclusion:Mesenchymal cell-cell interaction with neutrophils was remarkable for therapeutic strategies in diseases associated with neutrophil function in response to physiological and pathological cell therapy with MSCs. M3 ER -